(Q24201928)

2

Rui

Guo

1 reference

9 December 2023

Fubo Zhang

3

Fubo

Zhang

1 reference

9 December 2023

Chao Zhang

4

Chao

Zhang

1 reference

9 December 2023

Shuai Dong

5

Shuai

Dong

1 reference

9 December 2023

Hongyu Zhou

6

Hongyu

Cochrane Database of Systematic Reviews

Zhou

1 reference

9 December 2023

6 December 2013

0 references

published in

0 references

cites work

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Validation of the functional assessment of multiple sclerosis quality of life instrument

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Natural history of multiple sclerosis: a unifying concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Recent developments in the assessment of quality of life in multiple sclerosis (MS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Burden of a multiple sclerosis relapse: the patient's perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Antibodies against CD20 (rituximab) for treating multiple sclerosis: US20100233121.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3

Rituximab for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD009130.PUB3